Study shows GE Healthcare’s VisipaqueTM associated with lower incidence of Contrast-Induced Nephropathy and Cardiovascular Events in patients with Chronic Kidney Disease compared to iopromide
Dubai, UAE; February 4, 2009: A first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of GE Healthcare’s isosmolar contrast media (CM) iodixanol (Visipaque) and the low-osmolar CM iopromide in select patients concluded iodixanol is associated with lower incidence of contrast-induced neuropathy (CIN) and cardiovascular events (CV) than [...]